BDBM171853 US9085584, 22::US9085584, 23::US9085584, 24

SMILES Cc1nc2cccnc2n2c(nnc12)-c1cc(OC2CCOC2)ccc1Cl

InChI Key InChIKey=RBIPQUPPQHENAE-UHFFFAOYSA-N

Data  10 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 10 hits for monomerid = 171853   

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM171853(US9085584, 23 | US9085584, 24 | US9085584, 22)
Affinity DataIC50: 71nMT: 2°CAssay Description:For all experiments the Phosphodiesterase [3H]cAMP SPA Enzyme Assay (TRKQ7090, GE Healthcare Europe GmbH) were used. The enzymatic activity of the PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2016
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM171853(US9085584, 23 | US9085584, 24 | US9085584, 22)
Affinity DataIC50: 115nMT: 2°CAssay Description:For all experiments the Phosphodiesterase [3H]cAMP SPA Enzyme Assay (TRKQ7090, GE Healthcare Europe GmbH) were used. The enzymatic activity of the PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2016
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM171853(US9085584, 23 | US9085584, 24 | US9085584, 22)
Affinity DataIC50: 138nMT: 2°CAssay Description:For all experiments the Phosphodiesterase [3H]cAMP SPA Enzyme Assay (TRKQ7090, GE Healthcare Europe GmbH) were used. The enzymatic activity of the PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2016
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM171853(US9085584, 23 | US9085584, 24 | US9085584, 22)
Affinity DataIC50: 207nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2016
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM171853(US9085584, 23 | US9085584, 24 | US9085584, 22)
Affinity DataIC50: 216nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2016
Entry Details
US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM171853(US9085584, 23 | US9085584, 24 | US9085584, 22)
Affinity DataIC50: 5.00E+3nMT: 2°CAssay Description:For assessing activity of compounds on PDE10 inhibition, the following modifications of the protocol described below are applied: protein amount: ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2016
Entry Details
US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM171853(US9085584, 23 | US9085584, 24 | US9085584, 22)
Affinity DataIC50: 5.10E+3nMT: 2°CAssay Description:For assessing activity of compounds on PDE10 inhibition, the following modifications of the protocol described below are applied: protein amount: ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2016
Entry Details
US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM171853(US9085584, 23 | US9085584, 24 | US9085584, 22)
Affinity DataIC50: 6.69E+3nMT: 2°CAssay Description:For assessing activity of compounds on PDE10 inhibition, the following modifications of the protocol described below are applied: protein amount: ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2016
Entry Details
US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM171853(US9085584, 23 | US9085584, 24 | US9085584, 22)
Affinity DataIC50: 9.19E+3nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2016
Entry Details
US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM171853(US9085584, 23 | US9085584, 24 | US9085584, 22)
Affinity DataIC50: 9.32E+3nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2016
Entry Details
US Patent